Evidence map›Paper›PMID 25492614›Full record

ArticleActa neuropathologica communications2014

Immunoreactivity of valosin-containing protein in sporadic amyotrophic lateral sclerosis and in a case of its novel mutant.

Takashi Ayaki, Hidefumi Ito, Hiroko Fukushima, Takeshi Inoue, Takayuki Kondo, Akito Ikemoto, Takeshi Asano, Akemi Shodai, Takuji Fujita, Satoshi Fukui and 10 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Acta neuropathologica communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 45 citations in OpenAlex.

  1. Astrocyte-Predominant Tau Pathology in a Patient With VCP R191Q Variant.Neuropathology : official journal of the Japanese Society of Neuropathology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. VCP-related myopathy: a case series and a review of literature.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2023
    Review
  10. Review
  11. Valosin Containing Protein (VCP): A Multistep Regulator of Autophagy.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Molecular and Cellular Mechanisms Affected in ALS.Journal of personalized medicine · 2020
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 1 country.

Takashi AyakiDepartment of Neurology, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8510, Japan. ayaki520@kuhp.kyoto-u.ac.jp.
Hidefumi ItoDepartment of Neurology, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8510, Japan. ito@wakayama-med.ac.jp.
Hiroko FukushimaDepartment of Pathology, Osaka City General Hospital, 2-13-22, Miyakojima-Hondori, Miyakojima-ku, Osaka, 534-0021, Japan. hir-fukushima@med.osakacity-hp.or.jp.
Takeshi InoueDepartment of Pathology, Osaka City General Hospital, 2-13-22, Miyakojima-Hondori, Miyakojima-ku, Osaka, 534-0021, Japan. m1657676@msic.med.osaka-cu.ac.jp.
Takayuki KondoCenter for iPS Cell Research and Application, Kyoto University, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. kondotak@kuhp.kyoto-u.ac.jp.
Akito IkemotoKyoto Municipal Rehabilitation Center for Physically Disabled People, 30, Mibusennen-cho, Nakagyo-ku,, Kyoto, 604-8854, Japan. akito@kuhp.kyoto-u.ac.jp.
Takeshi AsanoDepartment of Neurology, Kyoto University Graduate School of Medicine, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. tasano@kuhp.kyoto-u.ac.jp.
Akemi ShodaiDepartment of Neurology, Kyoto University Graduate School of Medicine, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. shodai@kuhp.kyoto-u.ac.jp.
Takuji FujitaTakumi Medical Corporation, Neurology Clinic, 7-8, Takarayama-cho, Toyonaka, Osaka, 561-0893, Japan. fujita-okhc@healthcarenet.jp.
Satoshi FukuiTazuke Kofukai Foundation, Medical Research Institute and Kitano Hospital, 2-4-20, Ohgimachi, Kita-ku, Osaka, 530-8480, Japan. sfukui@kitano-hp.or.jp.
Hiroyuki MorinoDepartment of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan. morino@hiroshima-u.ac.jp.
Satoshi NakanoDepartment of Neurology, Osaka City General Hospital, 2-13-22, Miyakojima-Hondori, Miyakojima-ku, Osaka, 534-0021, Japan. s-nakano@med.osakacity-hp.or.jp.
Hirofumi KusakaDepartment of Neurology, Kansai Medical University, 2-5-1, Shin-machi, Hirakata, Osaka, 573-1010, Japan. kusaka@hirakata.kmu.ac.jp.
Hirofumi YamashitaDepartment of Neurology, Kyoto University Graduate School of Medicine, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. hirofumi@kuhp.kyoto-u.ac.jp.
Masafumi IharaDepartment of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, 5-7-1, Fujishirodai, Suita, Osaka, 565-8565, Japan. ihara@kuhp.kyoto-u.ac.jp.
Riki MatsumotoDepartment of Neurology, Kyoto University Graduate School of Medicine, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. matsumot@kuhp.kyoto-u.ac.jp.
Jun KawamataDepartment of Neurology, School of Medicine, Sapporo Medical University, South 1 West 17, Chuo-ku, Sapporo, Hokkaido, 060-8556, Japan. kawamata@kuhp.kyoto-u.ac.jp.
Makoto UrushitaniDepartment of Neurology, Kyoto University Graduate School of Medicine, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. urumak@kuhp.kyoto-u.ac.jp.
Hideshi KawakamiDepartment of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan. kawakamihideshi@gmail.com.
Ryosuke TakahashiDepartment of Neurology, Kyoto University Graduate School of Medicine, 53, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. ryosuket@kuhp.kyoto-u.ac.jp.
Kyoto University · JPOsaka City General Hospital · JPHiroshima University · JPWakayama Medical University · JPKansai Medical University · JPKitano Hospital · JPKyoto Prefectural Education Center · JPNational Cerebral and Cardiovascular Center · JPSapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMutations in the valosin-containing protein (VCP) gene were first found to cause inclusion- body myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD). Mutations in the VCP gene were later reported to occur in familial amyotrophic lateral sclerosis (ALS). But the role of VCP in the neurodegenerative processes that occur in ALS remains unknown. The purpose of the present study was to elucidate the role of VCP in the neurodegeneration seen in sporadic and VCP mutant ALS.

resultsImmunohistochemistry demonstrated that the frequency of distinct VCP-positive nuclei of spinal motor neurons of patients with sporadic ALS (SALS) and the ALS with VCP novel mutation (ALS-VCP, M158V) was increased, compared with that of the control cases. No VCP-positive inclusion bodies were observed in SALS patients, a ALS-VCP patient or in control subjects. Neuropathologic examination of the ALS-VCP case showed loss of motor neurons, the presence of Bunina bodies, and degeneration of the corticospinal tracts. Bunina bodies detected in this case were confirmed to show immunohistochemical and ultrastructural features similar to those previously described. Furthermore, neuronal intracytoplasmic inclusions immunopositive for TAR DNA-binding protein 43 kDa (TDP-43), phosphorylated TDP-43, ubiquitin (Ub), p62, and optineurin were identified in the spinal and medullary motoneurons, but not in the neocortex. Gene analysis of this ALS-VCP patient confirmed the de novo mutation of M158V, which was not found in control cases; and bioinformatics using several in silico analyses showed possible damage to the structure of VCP. Immunocytochemical study of cultured cells showed increased cytoplasmic translocation of TDP-43 in cells transfected with several mutant VCP including our patient's compared with wild-type VCP.

conclusionThese findings support the idea that VCP is associated with the pathomechanism of SALS and familial ALS with a VCP mutation, presumably acting through a dominant-negative mechanism.

Indexed as

Adenosine TriphosphatasesAdultAgedAged, 80 and overAmyotrophic Lateral SclerosisBrainCell Cycle ProteinsCell Line, TumorFemaleHEK293 CellsHumansMaleMiddle AgedMutationSpinal CordValosin Containing ProteinAdenosine TriphosphatasesCell Cycle ProteinsValosin Containing ProteinVCP protein, human

Identifiers

PMID25492614
PMCPMC4297454
OpenAlexW2124966531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.